Chapter 1. Research Scope

1.1. Research Objectives

1.2. Market Definition

1.3. Analysis Period

1.4. Market Size Breakdown by Segments

1.4.1. Market size breakdown, by technology

1.4.2. Market size breakdown, by offering

1.4.3. Market size breakdown, by transplant type

1.4.4. Market size breakdown, by end user

1.4.5. Market size breakdown, by application

1.4.6. Market size breakdown, by region

1.4.7. Market size breakdown, by country

1.5. Market Data Reporting Unit

1.5.1. Value

1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.1.1. Paid

2.1.2. Unpaid

2.1.3. P&S Intelligence database

2.2. Primary Research

2.3. Market Size Estimation

2.4. Data Triangulation

2.5. Currency Conversion Rates

2.6. Assumptions for the Study

2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics

5.1.1. Trends

5.1.2. Drivers

5.1.3. Restraints/challenges

5.1.4. Impact analysis of drivers/restraints

5.2. Impact of COVID-19

5.3. Porter’s Five Forces Analysis

5.3.1. Bargaining power of buyers

5.3.2. Bargaining power of suppliers

5.3.3. Threat of new entrants

5.3.4. Intensity of rivalry

5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview

6.2. Market Revenue, by Technology (2017–2030)

6.2.1. Molecular assay market revenue, by type (2017–2030)

6.2.2. Non-molecular assay market revenue, by type (2017–2030)

6.3. Market Revenue, by Offering (2017–2030)

6.4. Market Revenue, by Transplant Type (2017–2030)

6.4.1. Solid organ market revenue, by type (2017–2030)

6.5. Market Revenue, by Application (2017–2030)

6.6. Market Revenue, by End User (2017–2030)

6.7. Market Revenue, by Region (2017–2030)

Chapter 7. North America Market

7.1. Overview

7.2. Market Revenue, by Technology (2017–2030)

7.2.1. Molecular assay market revenue, by type (2017–2030)

7.2.2. Non-molecular assay market revenue, by type (2017–2030)

7.3. Market Revenue, by Offering (2017–2030)

7.4. Market Revenue, by Transplant Type (2017–2030)

7.4.1. Solid organ market revenue, by type (2017–2030)

7.5. Market Revenue, by Application (2017–2030)

7.6. Market Revenue, by End User (2017–2030)

7.7. Market Revenue, by Country (2017–2030)

Chapter 8. Europe Market

8.1. Overview

8.2. Market Revenue, by Technology (2017–2030)

8.2.1. Molecular assay market revenue, by type (2017–2030)

8.2.2. Non-molecular assay market revenue, by type (2017–2030)

8.3. Market Revenue, by Offering (2017–2030)

8.4. Market Revenue, by Transplant Type (2017–2030)

8.4.1. Solid organ market revenue, by type (2017–2030)

8.5. Market Revenue, by Application (2017–2030)

8.6. Market Revenue, by End User (2017–2030)

8.7. Market Revenue, by Country (2017–2030)

Chapter 9. APAC Market

9.1. Overview

9.2. Market Revenue, by Technology (2017–2030)

9.2.1. Molecular assay market revenue, by type (2017–2030)

9.2.2. Non-molecular assay market revenue, by type (2017–2030)

9.3. Market Revenue, by Offering (2017–2030)

9.4. Market Revenue, by Transplant Type (2017–2030)

9.4.1. Solid organ market revenue, by type (2017–2030)

9.5. Market Revenue, by Application (2017–2030)

9.6. Market Revenue, by End User (2017–2030)

9.7. Market Revenue, by Country (2017–2030)

Chapter 10. LATAM Market

10.1. Overview

10.2. Market Revenue, by Technology (2017–2030)

10.2.1. Molecular assay market revenue, by type (2017–2030)

10.2.2. Non-molecular assay market revenue, by type (2017–2030)

10.3. Market Revenue, by Offering (2017–2030)

10.4. Market Revenue, by Transplant Type (2017–2030)

10.4.1. Solid organ market revenue, by type (2017–2030)

10.5. Market Revenue, by Application (2017–2030)

10.6. Market Revenue, by End User (2017–2030)

10.7. Market Revenue, by Country (2017–2030)

Chapter 11. MEA Market

11.1. Overview

11.2. Market Revenue, by Technology (2017–2030)

11.2.1. Molecular assay market revenue, by type (2017–2030)

11.2.2. Non-molecular assay market revenue, by type (2017–2030)

11.3. Market Revenue, by Offering (2017–2030)

11.4. Market Revenue, by Transplant Type (2017–2030)

11.4.1. Solid organ market revenue, by type (2017–2030)

11.5. Market Revenue, by Application (2017–2030)

11.6. Market Revenue, by End User (2017–2030)

11.7. Market Revenue, by Country (2017–2030)

Chapter 12. U.S. Market

12.1. Overview

12.2. Market Revenue, by Technology (2017–2030)

12.2.1. Molecular assay market revenue, by type (2017–2030)

12.2.2. Non-molecular assay market revenue, by type (2017–2030)

12.3. Market Revenue, by Offering (2017–2030)

12.4. Market Revenue, by Transplant Type (2017–2030)

12.4.1. Solid organ market revenue, by type (2017–2030)

12.5. Market Revenue, by Application (2017–2030)

12.6. Market Revenue, by End User (2017–2030)

Chapter 13. Canada Market

13.1. Overview

13.2. Market Revenue, by Technology (2017–2030)

13.2.1. Molecular assay market revenue, by type (2017–2030)

13.2.2. Non-molecular assay market revenue, by type (2017–2030)

13.3. Market Revenue, by Offering (2017–2030)

13.4. Market Revenue, by Transplant Type (2017–2030)

13.4.1. Solid organ market revenue, by type (2017–2030)

13.5. Market Revenue, by Application (2017–2030)

13.6. Market Revenue, by End User (2017–2030)

Chapter 14. Germany Market

14.1. Overview

14.2. Market Revenue, by Technology (2017–2030)

14.2.1. Molecular assay market revenue, by type (2017–2030)

14.2.2. Non-molecular assay market revenue, by type (2017–2030)

14.3. Market Revenue, by Offering (2017–2030)

14.4. Market Revenue, by Transplant Type (2017–2030)

14.4.1. Solid organ market revenue, by type (2017–2030)

14.5. Market Revenue, by Application (2017–2030)

14.6. Market Revenue, by End User (2017–2030)

Chapter 15. France Market

15.1. Overview

15.2. Market Revenue, by Technology (2017–2030)

15.2.1. Molecular assay market revenue, by type (2017–2030)

15.2.2. Non-molecular assay market revenue, by type (2017–2030)

15.3. Market Revenue, by Offering (2017–2030)

15.4. Market Revenue, by Transplant Type (2017–2030)

15.4.1. Solid organ market revenue, by type (2017–2030)

15.5. Market Revenue, by Application (2017–2030)

15.6. Market Revenue, by End User (2017–2030)

Chapter 16. U.K. Market

16.1. Overview

16.2. Market Revenue, by Technology (2017–2030)

16.2.1. Molecular assay market revenue, by type (2017–2030)

16.2.2. Non-molecular assay market revenue, by type (2017–2030)

16.3. Market Revenue, by Offering (2017–2030)

16.4. Market Revenue, by Transplant Type (2017–2030)

16.4.1. Solid organ market revenue, by type (2017–2030)

16.5. Market Revenue, by Application (2017–2030)

16.6. Market Revenue, by End User (2017–2030)

Chapter 17. Italy Market

17.1. Overview

17.2. Market Revenue, by Technology (2017–2030)

17.2.1. Molecular assay market revenue, by type (2017–2030)

17.2.2. Non-molecular assay market revenue, by type (2017–2030)

17.3. Market Revenue, by Offering (2017–2030)

17.4. Market Revenue, by Transplant Type (2017–2030)

17.4.1. Solid organ market revenue, by type (2017–2030)

17.5. Market Revenue, by Application (2017–2030)

17.6. Market Revenue, by End User (2017–2030)

Chapter 18. Spain Market

18.1. Overview

18.2. Market Revenue, by Technology (2017–2030)

18.2.1. Molecular assay market revenue, by type (2017–2030)

18.2.2. Non-molecular assay market revenue, by type (2017–2030)

18.3. Market Revenue, by Offering (2017–2030)

18.4. Market Revenue, by Transplant Type (2017–2030)

18.4.1. Solid organ market revenue, by type (2017–2030)

18.5. Market Revenue, by Application (2017–2030)

18.6. Market Revenue, by End User (2017–2030)

Chapter 19. Japan Market

19.1. Overview

19.2. Market Revenue, by Technology (2017–2030)

19.2.1. Molecular assay market revenue, by type (2017–2030)

19.2.2. Non-molecular assay market revenue, by type (2017–2030)

19.3. Market Revenue, by Offering (2017–2030)

19.4. Market Revenue, by Transplant Type (2017–2030)

19.4.1. Solid organ market revenue, by type (2017–2030)

19.5. Market Revenue, by Application (2017–2030)

19.6. Market Revenue, by End User (2017–2030)

Chapter 20. China Market

20.1. Overview

20.2. Market Revenue, by Technology (2017–2030)

20.2.1. Molecular assay market revenue, by type (2017–2030)

20.2.2. Non-molecular assay market revenue, by type (2017–2030)

20.3. Market Revenue, by Offering (2017–2030)

20.4. Market Revenue, by Transplant Type (2017–2030)

20.4.1. Solid organ market revenue, by type (2017–2030)

20.5. Market Revenue, by Application (2017–2030)

20.6. Market Revenue, by End User (2017–2030)

Chapter 21. India Market

21.1. Overview

21.2. Market Revenue, by Technology (2017–2030)

21.2.1. Molecular assay market revenue, by type (2017–2030)

21.2.2. Non-molecular assay market revenue, by type (2017–2030)

21.3. Market Revenue, by Offering (2017–2030)

21.4. Market Revenue, by Transplant Type (2017–2030)

21.4.1. Solid organ market revenue, by type (2017–2030)

21.5. Market Revenue, by Application (2017–2030)

21.6. Market Revenue, by End User (2017–2030)

Chapter 22. Australia Market

22.1. Overview

22.2. Market Revenue, by Technology (2017–2030)

22.2.1. Molecular assay market revenue, by type (2017–2030)

22.2.2. Non-molecular assay market revenue, by type (2017–2030)

22.3. Market Revenue, by Offering (2017–2030)

22.4. Market Revenue, by Transplant Type (2017–2030)

22.4.1. Solid organ market revenue, by type (2017–2030)

22.5. Market Revenue, by Application (2017–2030)

22.6. Market Revenue, by End User (2017–2030)

Chapter 23. South Korea Market

23.1. Overview

23.2. Market Revenue, by Technology (2017–2030)

23.2.1. Molecular assay market revenue, by type (2017–2030)

23.2.2. Non-molecular assay market revenue, by type (2017–2030)

23.3. Market Revenue, by Offering (2017–2030)

23.4. Market Revenue, by Transplant Type (2017–2030)

23.4.1. Solid organ market revenue, by type (2017–2030)

23.5. Market Revenue, by Application (2017–2030)

23.6. Market Revenue, by End User (2017–2030)

Chapter 24. Brazil Market

24.1. Overview

24.2. Market Revenue, by Technology (2017–2030)

24.2.1. Molecular assay market revenue, by type (2017–2030)

24.2.2. Non-molecular assay market revenue, by type (2017–2030)

24.3. Market Revenue, by Offering (2017–2030)

24.4. Market Revenue, by Transplant Type (2017–2030)

24.4.1. Solid organ market revenue, by type (2017–2030)

24.5. Market Revenue, by Application (2017–2030)

24.6. Market Revenue, by End User (2017–2030)

Chapter 25. Mexico Market

25.1. Overview

25.2. Market Revenue, by Technology (2017–2030)

25.2.1. Molecular assay market revenue, by type (2017–2030)

25.2.2. Non-molecular assay market revenue, by type (2017–2030)

25.3. Market Revenue, by Offering (2017–2030)

25.4. Market Revenue, by Transplant Type (2017–2030)

25.4.1. Solid organ market revenue, by type (2017–2030)

25.5. Market Revenue, by Application (2017–2030)

25.6. Market Revenue, by End User (2017–2030)

Chapter 26. Saudi Arabia Market

26.1. Overview

26.2. Market Revenue, by Technology (2017–2030)

26.2.1. Molecular assay market revenue, by type (2017–2030)

26.2.2. Non-molecular assay market revenue, by type (2017–2030)

26.3. Market Revenue, by Offering (2017–2030)

26.4. Market Revenue, by Transplant Type (2017–2030)

26.4.1. Solid organ market revenue, by type (2017–2030)

26.5. Market Revenue, by Application (2017–2030)

26.6. Market Revenue, by End User (2017–2030)

Chapter 27. South Africa Market

27.1. Overview

27.2. Market Revenue, by Technology (2017–2030)

27.2.1. Molecular assay market revenue, by type (2017–2030)

27.2.2. Non-molecular assay market revenue, by type (2017–2030)

27.3. Market Revenue, by Offering (2017–2030)

27.4. Market Revenue, by Transplant Type (2017–2030)

27.4.1. Solid organ market revenue, by type (2017–2030)

27.5. Market Revenue, by Application (2017–2030)

27.6. Market Revenue, by End User (2017–2030)

Chapter 28. U.A.E. Market

28.1. Overview

28.2. Market Revenue, by Technology (2017–2030)

28.2.1. Molecular assay market revenue, by type (2017–2030)

28.2.2. Non-molecular assay market revenue, by type (2017–2030)

28.3. Market Revenue, by Offering (2017–2030)

28.4. Market Revenue, by Transplant Type (2017–2030)

28.4.1. Solid organ market revenue, by type (2017–2030)

28.5. Market Revenue, by Application (2017–2030)

28.6. Market Revenue, by End User (2017–2030)

Chapter 29. Competitive Landscape

29.1. List of Market Players and their Offerings

29.2. Competitive Benchmarking of Key Players

29.3. Product Benchmarking of Key Players

29.4. Recent Strategic Developments

Chapter 30. Company Profiles

30.1. bioMérieux S.A.

30.1.1. Business overview

30.1.2. Product and service offerings

30.1.3. Key financial summary

30.2. Thermo Fisher Scientific Inc.

30.2.1. Business overview

30.2.2. Product and service offerings

30.2.3. Key financial summary

30.3. Bio-Rad Laboratories Inc.

30.3.1. Business overview

30.3.2. Product and service offerings

30.3.3. Key financial summary

30.4. Abbott Laboratories

30.4.1. Business overview

30.4.2. Product and service offerings

30.4.3. Key financial summary

30.5. Hologic Inc.

30.5.1. Business overview

30.5.2. Product and service offerings

30.5.3. Key financial summary

30.6. F. Hoffmann-La Roche Ltd.

30.6.1. Business overview

30.6.2. Product and service offerings

30.6.3. Key financial summary

30.7. Laboratory Corporation of America Holdings

30.7.1. Business overview

30.7.2. Product and service offerings

30.7.3. Key financial summary

30.8. BAG Diagnostics GmbH

30.8.1. Business overview

30.8.2. Product and service offerings

30.8.3. Key financial summary

30.9. Illumina Inc.

30.9.1. Business overview

30.9.2. Product and service offerings

30.9.3. Key financial summary

Chapter 31. Appendix

31.1. Abbreviations

31.2. Sources and References

31.3. Related Reports

※参考情報 移植診断とは、臓器移植においてドナーとレシピエントの適合性を評価するプロセスを指します。移植を成功させるためには、両者の免疫系がどれだけ適合しているかが非常に重要であり、この診断がその判断材料となります。移植における拒絶反応を防ぐため、適切な検査と評価が欠かせません。 移植診断にはいくつかの種類があります。まず、組織型適合性試験が挙げられます。これは、ドナーとレシピエントのHLA（ヒト白血球抗原）型を検査し、一致するかどうかを確認するものです。HLAは、体内の細胞が自己か非自己かを識別するために重要な役割を果たします。一致するほど、拒絶反応が起こりにくくなります。 次に、血清学的検査も重要です。これは、レシピエントの血液中にドナーに対する抗体が存在するかを調べるものです。抗体が検出されると、移植後に拒絶反応が起こるリスクが高まりますので、抗体の有無を確認することで移植の安全性を評価します。 さらに、遺伝子型解析も最近の移植診断のアプローチとして注目されています。次世代シーケンシング技術を用いて、より詳細にHLA遺伝子の多型を特定し、適合性を評価します。この方法は、従来の検査よりも高精度であり、より正確な適合性評価を可能にします。 移植診断は臓器移植の成功率を高めるだけでなく、患者の生命を守るためにも重要な役割を果たしています。正確な検査を通じて、患者にとって最適なドナーを選定することができ、不必要な拒絶反応のリスクを低減できます。 移植診断の用途は多岐にわたります。主に、腎臓、肝臓、心臓などの臓器移植において、ドナーとレシピエントの適合性を確認するために行われます。特に腎臓移植では、ドナーからの腎臓がレシピエントに対して適切であるかどうかを判断することが、長期的な機能維持において極めて重要です。心臓移植や肝臓移植でも同様に、発症する可能性のある拒絶反応を予防するために、詳細な適合性評価が必要になります。 関連技術としては、前述のHLA型間での親和性を評価するために使用されるさまざまな技術があります。それには、フローサイトメトリーやELISA（酵素結合免疫吸着法）などの免疫学的手法が含まれます。また、最近では大規模なデータ分析技術を利用して、多数のHLA型を比較することができるバイオインフォマティクスも利用されています。これらの技術は、移植に関する研究や適合性評価をより効率的に行うための鍵となります。 移植診断には倫理的な側面も存在します。臓器が不足している現状において、ドナーの選定や取り扱いについては慎重な判断が求められます。このため、ドナーからの臓器提供が公正であり、かつ選定基準が明確であることが、患者と社会全体にとって重要です。移植診断を通じて、適正な医療行為が維持されなければなりません。 総じて、移植診断は臓器移植の成功に不可欠な要素であり、臓器の適合性や拒絶反応のリスクを厳密に評価することで、患者の生命を救う可能性が高まります。医療技術の進展とともに、移植診断の精度や効率も向上しており、今後ますます重要性を増す分野です。そのため、適切な技術と倫理に基づいた判断が求められ続けるでしょう。